Nurix Therapeutics vs Precigen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nurix Therapeutics Inc (NRIX)

Q3 20269 Jul – 7 Aug 2026

▲4

Roche deal closes, Phase 3 starts, Sanofi milestone boosts Nurix

Roche collaboration closes with $700M upfront Nurix closed its global collaboration with Roche for bexobrutideg after antitrust clearance, receiving $700 million upfront and eligibility for up to $2.3 billion in milestones. This huge cash infusion strengthens Nurix's balance sheet and validates its BTK degrader, pushing the stock up.
The closing of the Roche deal is a major new event that directly boosts Nurix's capital and credibility.
First patient enrolled in Phase 3 DAYBreak CLL-306 trial Nurix enrolled the first patient in a pivotal Phase 3 trial of bexobrutideg for relapsed/refractory CLL/SLL, comparing it to standard-of-care pirtobrutinib. This advances the drug toward potential approval, increasing the chance of future revenue and lifting investor confidence.
The Phase 3 start is a new clinical milestone that de-risks bexobrutideg and supports the stock's upside.
Sanofi milestone payment of $10 million Nurix received a $10 million milestone from Sanofi for starting a Phase 1 trial of an oral STAT6 degrader, bringing total Sanofi receipts to about $139 million. This non-dilutive cash and partner validation support the pipeline and strengthen the financial position.
The Sanofi milestone is a new cash event that reinforces Nurix's partnership strategy and financial health.
Biotech sector rally lifts Nurix to 52-week high Nurix shares climbed to $25.49 as part of a broad biotech rally on August 7, 2026, driven by sector-wide earnings and pipeline progress. While this reflects general market enthusiasm, it also highlights Nurix's recent positive news flow.
The sector rally is a new market event that contributed to Nurix's stock price increase, though it is less company-specific.

July 20269 Jul – 7 Aug 2026

▲4

Roche deal closes, Phase 3 starts, Sanofi milestone boosts Nurix

Roche collaboration closes with $700M upfront Nurix closed its global collaboration with Roche for bexobrutideg after antitrust clearance, receiving $700 million upfront and eligibility for up to $2.3 billion in milestones. This huge cash infusion strengthens Nurix's balance sheet and validates its BTK degrader, pushing the stock up.
The closing of the Roche deal is a major new event that directly boosts Nurix's capital and credibility.
First patient enrolled in Phase 3 DAYBreak CLL-306 trial Nurix enrolled the first patient in a pivotal Phase 3 trial of bexobrutideg for relapsed/refractory CLL/SLL, comparing it to standard-of-care pirtobrutinib. This advances the drug toward potential approval, increasing the chance of future revenue and lifting investor confidence.
The Phase 3 start is a new clinical milestone that de-risks bexobrutideg and supports the stock's upside.
Sanofi milestone payment of $10 million Nurix received a $10 million milestone from Sanofi for starting a Phase 1 trial of an oral STAT6 degrader, bringing total Sanofi receipts to about $139 million. This non-dilutive cash and partner validation support the pipeline and strengthen the financial position.
The Sanofi milestone is a new cash event that reinforces Nurix's partnership strategy and financial health.
Biotech sector rally lifts Nurix to 52-week high Nurix shares climbed to $25.49 as part of a broad biotech rally on August 7, 2026, driven by sector-wide earnings and pipeline progress. While this reflects general market enthusiasm, it also highlights Nurix's recent positive news flow.
The sector rally is a new market event that contributed to Nurix's stock price increase, though it is less company-specific.

Latest9 Jul – 7 Aug 2026

▲4

Roche deal closes, Phase 3 starts, Sanofi milestone boosts Nurix

Roche collaboration closes with $700M upfront Nurix closed its global collaboration with Roche for bexobrutideg after antitrust clearance, receiving $700 million upfront and eligibility for up to $2.3 billion in milestones. This huge cash infusion strengthens Nurix's balance sheet and validates its BTK degrader, pushing the stock up.
The closing of the Roche deal is a major new event that directly boosts Nurix's capital and credibility.
First patient enrolled in Phase 3 DAYBreak CLL-306 trial Nurix enrolled the first patient in a pivotal Phase 3 trial of bexobrutideg for relapsed/refractory CLL/SLL, comparing it to standard-of-care pirtobrutinib. This advances the drug toward potential approval, increasing the chance of future revenue and lifting investor confidence.
The Phase 3 start is a new clinical milestone that de-risks bexobrutideg and supports the stock's upside.
Sanofi milestone payment of $10 million Nurix received a $10 million milestone from Sanofi for starting a Phase 1 trial of an oral STAT6 degrader, bringing total Sanofi receipts to about $139 million. This non-dilutive cash and partner validation support the pipeline and strengthen the financial position.
The Sanofi milestone is a new cash event that reinforces Nurix's partnership strategy and financial health.
Biotech sector rally lifts Nurix to 52-week high Nurix shares climbed to $25.49 as part of a broad biotech rally on August 7, 2026, driven by sector-wide earnings and pipeline progress. While this reflects general market enthusiasm, it also highlights Nurix's recent positive news flow.
The sector rally is a new market event that contributed to Nurix's stock price increase, though it is less company-specific.

Precigen Inc (PGEN)

Q3 202615 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

August 202615 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

Latest15 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.